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SUMMARY 
Background: Genetic background influences allergic immune responses to environmental 
stimuli.  Non-obese-diabetic (NOD) mice are highly susceptible to environmental stimuli.  
Little is known the interaction of autoimmune genetic factors with innate immunity in 
allergies, especially skin hypersensitivity.  
Objectives: We sought to study the interplay of innate immunity and autoimmune genetic 
factors in contact hypersensitivity (CHS) using various innate immune-deficient NOD mice. 
Methods: TLR2-, TLR9- and MyD88-deficient NOD mice were used to investigate CHS.  
The cellular mechanism was determined by flow cytometry in vitro and adoptive cell transfer 
in vivo.  To investigate the role of MyD88 in dendritic cells (DCs) in the CHS, we also used 
CD11c
MyD88+
MyD88
-/-
NOD mice, in which MyD88 is expressed only in CD11c
+
cells. 
Results: We found that innate immunity negatively regulates CHS as innate immune-
deficient
 
NOD mice developed exacerbated CHS accompanied by increased skin-migrating 
CD11c
+
 DCs expressing more MHC-II and CD80.  Moreover, MyD88
-/-
NOD mice had 
increased number of CD11c
+
CD207
-
CD103
+ 
DCs and activated T effector cells in the skin-
draining lymph nodes.  Strikingly, re-expression of MyD88 in CD11c
+
 DCs 
(CD11c
MyD88+
MyD88
-/-
NOD) restored hyper CHS to normal level in MyD88
-/-
NOD mice.   
Conclusion: Our results suggest that autoimmune prone NOD genetic background aggravates 
CHS regulated by innate immunity, through DCs and T effector cells. 
 
Key words: contact sensitivity, dendritic cells, non-obese diabetic (NOD) mouse, Toll-like 
receptor, Tregs  
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Introduction 
Cutaneous delayed-type hypersensitivity and related contact hypersensitivity (CHS) reactions 
are classical examples of antigen-specific T cell-mediated allergic immune responses in the 
skin (1).  CHS responses can be initiated by keratinocytes and dendritic cells (DCs) (2).  
Innate immunity also plays an indispensable role in the CHS response.  Our previous study 
showed that Toll-like receptor (TLR) 4 ligand, lipopolysaccharide (LPS), a common innate 
immune stimulus, can stimulate iNKT cells to produce IL-4 facilitating the B-1 B cell 
activation and recruitment of antigen-specific T effector cells in CHS reaction (3).  Jin and 
colleagues found that TLR2 deficient C57BL/6 mice expressed defective CHS responses with 
impaired ear swelling, reduced cellular infiltration, and decreased epidermal thickening and 
local IFN-γ expression (4).  Further study by Klekotka et al. demonstrated that the 
downstream adaptor protein MyD88, rather than upstream TLRs, mediates the CHS response 
(5).  
Genetic factors play an important role in skin immune responses including CHS.  Recent 
studies suggested that autoimmunity contributes to the susceptibility to allergies including 
skin allergy (6, 7).  The genetic background of the non-obese-diabetic (NOD) mouse carries 
multiple autoimmune susceptibility loci (8).  In addition to the unique MHC, NOD mice have 
several defects in non-MHC genetic loci including impaired T regulatory function (9).  NOD 
mice are mainly used for type 1 diabetes (T1D) studies; however, the NOD genetic 
background predisposes to other autoimmune disorders, such as arthritis (10), sialitis (11) and 
thyroiditis (12).  Human studies showed that T1D patients have increased incidence of allergy 
(13, 14).  However, little is known how the autoimmune genetic factors affect allergy.  To 
investigate the interaction of autoimmune genetic factors with innate immunity in the CHS 
response, we studied CHS immune responses using NOD mice deficient in innate immunity. 
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MATERIALS AND METHODS  
 
Mice 
Wild type (WT) NOD, TLR2
-/-
, TLR9
-/-
, MyD88
-/-
 and CD11c
MyD88+
MyD88
-/-
 mice, all on the 
NOD genetic background, were generated at Yale University.  IFN-γR-/-NOD mice were 
purchased from the Jackson Laboratory and maintained at Yale University.  The procedures 
applied in this study were approved by IACUC of Yale University and 1
st
 Local Ethics 
Committee of Jagiellonian University Medical College. 
 
Reagents 
Hapten picryl chloride (PCl, TNP-Cl – trinitrophenyl chloride) was from Chemical Alta 
(Edmonton, Canada); fluorescein isothiocyanate (FITC), dibutyl phthalate (DBP), protease 
inhibitor cocktails, SYBRgreen JumpStart Taq and bovine serum albumin (BSA) were from 
Sigma-Aldrich Co. (St Louis, MO); IFN-γ ELISA Set, biotinylated anti-mouse IgG1 mAb and 
TMB substrate were from BD Biosciences (San Jose, CA); TNP-BSA was from Biosearch 
Technologies (Petaluma, CA); streptavidin-horseradish peroxidase was from Vector 
Laboratories (Burlingame, CA); fluorochrome or biotin conjugated mAbs were from 
BioLegend (San Diego, CA); fixation and permeabilization buffer, anti-mouse CD16/CD32 
mAb and PE conjugated-anti-mouse FoxP3 mAb were from eBioscience (San Diego, CA).  
Complete RPMI medium contained 100 U/ml penicillin, 100 µg/ml streptomycin, 2 mM L-
glutamine,
 
25 mM HEPES, 5x10
–5
 M 2-ME, and 10% FBS. RPMI media and supplements 
were from Sigma-Aldrich Co. (St Louis, MO).  Heat-inactivated fetal bovine serum (FBS) 
was from Gemini Bio-Products (West Sacramento, CA).  Anti-mouse CD4 (GK 1.5) and CD8 
(TIB 105) hybridomas were generously provided by the late Dr. Charles Janeway Jr. (Yale 
University).  Magnetic beads conjugated with goat anti-rat IgG were from Qiagen (Valencia 
CA).  EasySep mouse CD11c positive selection kit was from STEMCELL Technologies 
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Canada Inc. (Vancouver, BC).  TRIzol Reagent was from Thermo Fisher Scientific (Waltham, 
MA).  Isopropyl alcohol and DEPT-treated water were from AmericanBio, Inc. (Natick, MA).  
iScript™ cDNA Synthesis Kit was from (BIO-RAD, Hercules, CA).  Primers for qPCR were 
synthesized by Sigma-Aldrich Co. (St Louis, MO).  Primer sequences for: IL-10 (F-
CTGGACAACATACTGCTAACCG, R-GGGCATCACTTCTACCAGGTAA), TGF-β (F-
AGCCCGAAGCGGACTACTAT, R-TTCCCGAATGTCTGACGTATT), IFN-γ (F-
CTGGCAAAAGGATGGTGACATG, R- TGGCAATACTCATGAATGCATCCTT), and 
GAPDH (F- AGGTCGGTGTGAACGGATTTG, R- TGTAGACCATGTAGTTGAGGTCA). 
 
Induction of CHS in vivo 
Mice were sensitized by application of 150µl of 5% picryl chloride (PCl, TNP-Cl) in acetone-
ethanol mixture to the shaved abdomen.  Four days later, all the mice were challenged on both 
ears with 10µl of 0.4% PCl in olive oil-acetone mixture.  For sensitization with fluorescein 
isothiocyanate (FITC), 400µl of 0.5% FITC in acetone and dibutyl phthalate was applied to 
shaved abdominal skin.  After 5 days, mice were challenged on the ears with 10µl of 0.1% 
FITC in the same solvent. The ear thickness was measured with a micrometer before and 24 h 
after challenge. 
 
Induction of CHS after CD11c
+
 DC transfer 
Donor mice were sensitized with 150µl of 5% PCl (7.5mg).  Three days later, CD11c
+
 DCs 
were isolated from ALNs using a CD11c isolation kit (StemCell Technology).  4x10
4
 CD11c
+
 
DCs were injected intradermally into two spots on the abdomen of the recipients.  The 
experimental and control mice were challenged with 10µl of 0.4% PCl 4 days later and CHS 
responses were tested 24 h after the challenge.  
 
7 
 
Lymphocyte proliferative response to trinitrophenyl (TNP) and IFN-γ concentration in 
cell culture supernatants 
Mice were sensitized with 5% PCl (150µl).  Four days after sensitization,
 
cell suspensions 
from ALNs were prepared.  ALNC (3x10
6
) cells were incubated with 100µg of mouse 
immunoglobulins conjugated with TNP (TNP40-Ig) in 1 ml complete RPMI medium for 48h.  
IFN-γ secretion was measured in the supernatants using an ELISA Set.  In proliferation assay, 
ALNC (3x10
5
/well) were cultured with different concentrations of TNP40-Ig, in 200µl of the 
complete RPMI medium for 48h.  After adding 0.5µCi/well [
3
H]-thymidine and additional 
18h incubation, the cells were harvested and [
3
H]-thymidine
 
incorporation was determined on 
a beta counter.  The background
 
(cultures without antigen) was subtracted
 
from the cpm of the 
cultures with antigen. 
 
Staining of lymphoid cells and flow cytometry analysis 
To determine the phenotype and migration of skin DCs into ALNs, ALNC were isolated 3 
days post FITC or PCl sensitization. Cells were washed and pre-incubated with 0.5µg of anti-
mouse CD16/CD32 mAb (Fc blocker) for 15min at 4°C followed by incubation with 
appropriate fluorochrome- or biotin-conjugated mAbs. An additional incubation with PE-
streptavidin was performed (at 4°C, for 30min) whenever biotin-conjugated mAb was used.  
For FoxP3 staining, ALNC and auricular ear draining lymph node cells (ELNC) were 
harvested from PCl-sensitized and ear challenged mice. Cells were incubated with Fc blocker 
and stained for surface markers. After washing, the cells were treated with fixation and 
permeabilization buffer followed by incubation with anti-mouse/rat FoxP3-PE mAb at 4°C 
for 30min before analyzing with flow cytometry.  Gating information for all the flow 
cytometry analysis is presented in Fig. S2. 
 
Antibody measurement 
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Mice were sensitized and challenged with PCl as described above. The sera were collected 
24h after challenge. TNP-specific antibodies were measured by ELISA. Briefly, 96-well 
plates were coated with bovine serum albumin (BSA) conjugated with TNP hapten (TNP-
BSA, 50µg/ml) or BSA (50µg/ml) alone in PBS, at 4°C overnight. After washing, the plates 
were blocked with PBS containing 10% FBS for 1h at room temperature (RT).  The tested 
samples and different concentrations of standard reagent were added in the wells and 
incubated for 2h at RT.  After washing, the plates were incubated with biotinylated anti-
mouse IgG1 mAb for 1h followed by incubation with streptavidin-horseradish peroxidase for 
30min.  The enzymatic reaction was stopped 30min after adding TMB substrate.  Colorimetric 
absorbance was determined at the wavelength 450nm. 
 
Cytokine mRNA expression in the skin 
Mice were sensitized with 5% PCl (150µl) on the shaved abdomen.  Five days later two skin 
punches (0.6cm) were collected from each mouse and homogenized in 1 ml TRIzol Reagent.  
RNA was precipitated by mixing the homogenates with 0.5 ml isopropyl alcohol and washed 
with 75% ethanol.  The air-dried RNA pellet was dissolved in DEPC-treated water.  cDNA 
was synthesized using iScript™ cDNA Synthesis Kit, according to the manufacturer's 
protocol.  Quantification of mRNA content for all cytokine genes and housekeeping gene 
GAPDH was performed in Real-Time Cycler.  The PCR reaction mix for each gene and 
GAPDH contains SYBR green JumpStart Taq, forward and reverse primers, DNase-free 
water, and cDNA template.  
 
Statistical analysis 
Student’s t-test or Mann Whitney’s test or ANOVA followed by Tukey’s test were used with 
Prism software.  p<0.05 was considered statistically significant. 
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RESULTS  
The role of TLRs and MyD88 in CHS response in NOD mice  
We first tested whether NOD mice, which are genetically prone to sterile inflammation, 
develop normal T cell-mediated CHS.  Our results showed that NOD mice had normal CHS 
response to PCl, which was mediated by CD4
+
 cells (Fig. S1a) and IFN-γ-dependent (Fig. 
S1b).  We then studied the role of innate immunity in CHS response in NOD mice.  TLRs 
comprise a major family of innate immune receptors involved in both innate and adaptive 
immune responses (15).  In the absence of TLR2, C57BL/6 mice resulted in significantly 
decreased CHS reaction compared to TLR2-sufficient C57BL/6 mice (4).  To determine the 
role of TLRs in CHS response in NOD mice, which are prone to autoinflammation (16), we 
tested TLR2- and TLR9-deficient NOD mice.  In contrast to the published data in TLR2
-/-
 
C57BL/6 strain, our results demonstrate that the CHS immune response was markedly 
increased in TLR2- or TLR9-deficient NOD mice (Fig. 1a, groups D and F vs B).  To confirm 
the hyper-CHS response seen in vivo we examined the antigen specific response of ALNC in 
vitro.  In line with the ear swelling results, ALNC from TLR2- or TLR9-deficient NOD mice 
showed significantly stronger responses to TNP-Ig compared with WT NOD mice (Fig. 1b, 
groups B and C vs A).  As MyD88 plays a crucial role downstream of the TLR2 and TLR9 
signaling pathway (15), next, we studied CHS responses in MyD88
-/-
NOD mice.  Consistent 
with the augmented CHS response seen in TLR2
-/-
 or TLR9
-/-
 NOD mice, MyD88
-/-
NOD mice 
also showed hyper-CHS responses compared to WT NOD mice (Fig. 1a, group H vs B).  The 
in vivo hyper-response in MyD88
-/-
NOD mice was further confirmed by significantly stronger 
antigen-specific responses of ALNC in vitro (Fig. 1b, group D vs A). 
 
The importance of MyD88 expression in DCs and hyper-CHS responses in NOD mice 
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To investigate the cellular mechanism by which NOD mice develop hyper-CHS immune 
responses in the absence of TLRs or MyD88, we examined the phenotype of DCs, which are 
known to express high levels of TLRs (17) and are essential in CHS induction (18).  We 
found a significantly higher percentage of CD11c
+
DCs in TLR2- or TLR9- and MyD88-
deficient NOD mice that expressed the costimulatory molecule CD80 and the NOD MHC 
class II molecule I-A
g7 
(Figs 2a and 2b).  Our data suggest that DCs involved in the CHS 
response are more activated in innate immunity deficient NOD mice.  DCs are known to have 
a potent ability to present antigens to T cells and induce effective immune responses (19, 20) 
or contribute to induction of antigen-specific FoxP3
+ 
T regulatory cells (Tregs) (21).  As 
MyD88 is essential signaling molecule downstream of most of the TLRs (15) therefore we 
studied the effect of MyD88 on the function of CD11c
+ 
DCs and tested their ability to induce 
CHS responses in vivo.  Fig. 2c showed that CD11c
+
 cells isolated from MyD88
-/-
NOD mice 
were stronger inducers of CHS response than CD11c
+
 cells isolated from WT NOD mice 
(group C vs B).  Moreover, MyD88
-/-
NOD mice had higher IFN-γ and lower IL-10 and TGF-
β mRNA expression in the skin compared to the WT NOD mice (Fig. 2d, group B vs A).  
Thus, our results suggest that DCs play an important role in allergenic response in the skin 
and the hyper-CHS response found in MyD88
-/-
NOD mice is most likely due to the deficiency 
of MyD88 in DCs.  
To further investigate the role of MyD88 in DCs in the CHS response, we generated 
CD11c
MyD88+
MyD88
-/-
NOD mice, in which MyD88 is only expressed in CD11c
+
cells (22).  It 
is intriguing that “rescuing” MyD88 expression in CD11c
+
DCs completely restored the hyper-
CHS responses in MyD88
-/-
NOD mice to normal CHS responses seen in WT NOD mice (Fig. 
3a, group F vs D and B).  The in vivo skin inflammatory response was further confirmed by 
the results of antigen-specific ALNC proliferation in vitro (Fig. 3b) and their IFN-γ 
production (Fig. 3c).  Moreover, we found that the hyper-CHS response to PCl in MyD88
-/-
NOD mice was accompanied by a highly significant increase of TNP-specific IgG1 antibodies 
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compared to WT NOD mice (Fig. 3d, group D vs B).  Importantly, expression of MyD88 in 
CD11c
+
 DCs also restored the level of TNP-specific IgG1 antibody to that found in the WT 
mice (Fig. 3d, group F vs B).  
It is known that both Langerhans cells (LCs) and dermal dendritic cells (DDCs) 
migrate into skin-draining lymph nodes (LNs) to present antigen to naïve T lymphocytes in 
the initiation phase of skin immune responses (23).  To test whether hyper-CHS seen in 
MyD88
-/-
NOD mice is associated with alterations in DC migration, we tested DC migration in 
vivo in FITC-induced CHS reactions in order to trace the DC migration.  Similar to the results 
using PCl, MyD88
-/-
NOD mice also expressed hyper-reactivity to FITC (Fig. 4a, group D vs 
B).  To examine DC migration, we analyzed FITC
+
DCs from ALNs by flow cytometry.  
There was a significantly higher frequency of migrating DCs (FITC
+
CD11c
+
) co-expressing 
NOD MHC class II molecule I-A
g7
, co-stimulatory molecules CD80 and CD86 in ALNs of 
MyD88
-/-
NOD mice when compared to control NOD mice (Figs 4 b-e, group B vs A).  
However, the restoration of MyD88 expression in CD11c
+
DCs led to a similar DC migration 
and phenotype in MyD88
-/-
NOD to that seen in WT mice (Figs 4 b-e, group C vs A).  We also 
investigated the expression of langerin (CD207) and integrin (CD103), in migrating DCs.  
Our results showed a significantly higher frequency of FITC
+
CD11c
+
CD103
+
CD207
- 
DCs but 
lower percentage of FITC
+
CD11c
+
CD103
-
CD207
+
 cells in MyD88
-/-
NOD mice compared to 
WT or CD11c
MyD88+
MyD88
-/-
NOD mice (Figs 4f and 4g, group B vs A), whereas other DC 
subsets, such as FITC
+
CD11c
+
CD103
+
CD207
+
 and FITC
+
CD11c
+
CD103
-
CD207
-
, were 
similar (data not shown). 
 
MyD88
-/-
NOD mice have increased numbers of CD4
+
CD25
+
FoxP3
- 
activated T cells in 
ALNs  
It has been suggested that CD207
+
 DCs could induce FoxP3
+
 Tregs (24).  We hypothesized 
that a lower frequency of CD207
+
 DCs might indicate fewer FoxP3
+
 Tregs in MyD88-/-NOD 
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mice. Interestingly, the frequencies of CD4
+
CD25
+
FoxP3
+
 Tregs were similar in WT, 
MyD88
-/-
 and CD11c
MyD88+
MyD88
-/-
NOD mice in ALNs and auricular ear draining lymph 
nodes (ELNs) (Fig. 5a).  In contract, there was a higher percentage of CD4
+
CD25
+
Foxp3
-
 
activated effector T cells in both ALNs and ELNs cells from MyD88
-/-
NOD mice after CHS 
induction (Fig. 5b, group B vs A), leading a decreased ratio of Tregs to T effector cells in LNs 
(Fig. 5c).  However, the re-expression of MyD88 in CD11c
+
 cells restored the frequency of 
CD4
+
 T effector cells in LNs to those seen in the control mice (Fig. 5b, group C vs A) as well 
as the ratio of Tregs to T-effector-cells (Fig. 5c, group C vs group A). 
 
DISCUSSION  
Our novel findings in this study are i) innate immunity mediated by TLRs and MyD88 plays a 
protective role in CHS responses in autoimmune prone NOD genetic background, which is in 
contrast to the previously reported in C57BL/6 strain; ii) DCs are important innate cells in 
CHS responses and intriguingly, iii) the expression of MyD88 in DCs is essential in 
regulating CHS responses. 
The NOD mouse has been an important model of T1D for many years (25).  The NOD mice 
are genetically prone to immune dysregulation, which promotes multi-organ auto-
inflammation (16) and allergy (26, 27).  Studies have shown that human subjects with 
autoimmune disorders are more susceptible to allergy (28, 29, 30).  Additionally, the 
association of the innate immunity with genetic makeup, such as C57BL/6 vs NOD, is not 
known and there has not been published study about CHS response in NOD mice and to our 
knowledge, our current work is the first investigation in the literature.  Thus far, most of CHS 
studies in the literature used mice on C57BL/6 background.  It is important to investigate 
different genetic backgrounds in order to get closer to translational research as the genetic 
makeup in human subjects is very different and highly divers.  Thus, we believe that our study 
will provide important information to the scientific community and the public that contact 
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allergy can be very different in different genetic background.  The aim of our study was to 
characterize innate immune mechanisms involved in CHS responses in NOD mice. It is clear 
that TLRs play an important role in CHS reactions in non-autoimmune prone mouse strains 
(31, 4).  What was not clear is the role of TLRs in the CHS response in NOD strain, 
considering the multiple autoimmune prone loci of the NOD genetic background.  Our study 
demonstrated that TLRs play a protective role in CHS response in NOD mice, as in the 
absence of TLR2 or TLR9, NOD mice showed significantly exacerbated CHS response to PCl 
in vivo and in vitro.  Importantly, the hyper-CHS response was even greater in MyD88-
deficient NOD mice, which suggested that the enhanced CHS response seen in TLR2- or 
TLR9-deficient NOD mice is MyD88 dependent.  This is in sharp contrast to the published 
reports in MyD88-deficient C57BL/6 mice, which cannot mount CHS responses (31, 5).  Our 
results support a recent study that MyD88
-/-
NOD mice developed more severe asthma 
symptoms than WT mice after airway immunization with ovalbumin (32).  Thus, our data in 
CHS responses and the data from others in airway allergy strongly suggest that MyD88 and 
its dependent TLR2 and TLR9 molecules function as negative regulators in allergic responses 
in auto-inflammation prone NOD mice.  
The most important finding of our study is the role of DCs in the hyper-CHS response via 
MyD88.  It is known that DCs express a broad repertoire of innate receptors (33) and skin 
DCs carry dermal antigens including haptens migrate to the local LNs where they prime 
antigen-specific T cells and induce the expression of skin-specific homing receptors on the 
primed T cells (34).  It is conceivable that the hyper-CHS response in NOD mice, in the 
absence of TLR2, TLR9 or MyD88, is due to altered function of DCs.  To test this hypothesis 
we examined the DC phenotype and their migration in these mice.  We found a higher 
percentage of CD80
+
CD11c
+
IA
g7+
 DCs in ALNs of PCl sensitized TLR- and MyD88-
deficient NOD mice compared with NOD controls. Moreover, we found an increased 
percentage of migrating FITC
+
CD11c
+
 DCs in ALNC of MyD88
-/-
NOD mice, which had 
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hyper-CHS responses.  It is remarkable that re-expression of MyD88 in DCs restored not only 
the percentage of migrating DCs but also normal CHS responses in vivo and in vitro to the 
level seen in WT mice.  Our results provide direct evidence that DCs play an important role in 
CHS response and that MyD88 is critical in modulating the migration and function of DCs in 
CHS reactions.   
It was previously reported that during inflammation, DDCs are rapidly mobilized from the 
skin and home to draining LNs within 48 h, preceding the arrival of LCs (35).  Recent studies 
in C57BL/6 mice have revealed the role of MyD88 in DC migration and priming of naive 
CD4
+
 T-cell responses (36, 37).  However, Langerhans cells do not require MyD88-dependent 
signals for migration in CD8-mediated CHS to DNFB in C57BL/6 mice (38).  In our model of 
CD4-mediated CHS to PCl we found that sensitized MyD88
-/-
NOD mice had a decreased 
ratio of Tregs (CD4
+
CD25
+
FoxP3
+
) to activated T cells (CD4
+
CD25
+
FoxP3
-
) in ALNs and 
ELNs.  Studies using ovalbumin as antigen showed that either Langerin
+
 DDC (39) or CD103
-
 
DCs (40) induced Tregs in C57BL/6 mice.  In NOD mice, we found an increased frequency 
of migrating CD11c
+
CD103
+
CD207
-
 DDCs but decreased frequency of migrating 
CD11c
+
CD103
-
CD207
+
 LCs in ALNs, in the absence of MyD88.  Interestingly, re-expression 
of MyD88 in CD11c
+
 DCs reversed the above migration phenotype to resemble that seen in 
WT NOD mice.  It is thought that in the skin-draining LNs, CD103
+
 DDCs are responsible for 
cross-priming naïve T cells and likely induce Th1-type immune responses (41).  In contrast, 
epidermal CD207
+
CD103
-
 LCs promote Th17 responses to extracellular pathogens, which 
may ultimately lead to tolerance/anergy (42).  In addition, bacteria-primed LCs can drive the 
development of CD4
+
Foxp3
+
 Tregs (43).  Thus, it is possible that the enhanced CHS response 
in TLR- and MyD88-deficient NOD mice is associated with enriched percentages of Th1-
inducing CD103
+
 DDCs in the draining LNs.  Decreased percentages of tolerizing CD103
-
CD207
+
 DDCs in the draining LNs in TLR- and MyD88-deficient NOD mice do not seem to 
play a role in upregulation of CHS as the level of Treg cells in LNs is similar in knock out and 
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WT NOD mice.  This is also consistent with our results of stronger CHS response in NOD 
recipients after transfer of CD11c
+
 cells from MyD88
-/-
NOD donors.  Higher percentage of 
CD4
+
 T effector cells also results in a decreased ratio of CD4
+
CD25
+
FoxP3
+
 
Treg/CD4
+
CD25
+
FoxP3
-
 activated T cells in LNs of MyD88-deficient NOD mice.  It is 
conceivable that the hyper-CHS response and the increase of T effector CD4
+ 
cells found in 
MyD88-deficient NOD mice is due to lack of MyD88 in CD11c
+
 DCs and re-expression of 
MyD88 in CD11c
+
 DCs restores the phenotype to that observed in WT NOD mice.  
Increasing evidence suggests that IL-10 is an important link in the regulatory network of DCs, 
Treg and T effector cells, to prevent excessive immune response [44].  Using DC specific 
deletion of IL-10 receptor (IL-10R) mouse, Girard-Madoux M.J.H. et al. demonstrated that 
DCs are essential to prevent exacerbated T effector cell reactivation in the skin [44].  Our 
finding of the enhanced CHS but decreased IL-10 expression in the skin in MyD88
-/-
NOD 
mice comparing to WT NOD mice is in line with Girard-Madoux’s results in DC specific 
deletion of IL-10R mouse.  In summary, our current study provides novel insight into the role 
of genetic background in CHS responses and the protective role of innate immunity in the 
auto-inflammation prone NOD mouse strain.  More importantly, we revealed direct evidence 
that MyD88 is critical in modulating CHS reaction via DCs. 
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FIGURE LEGENDS  
 
Fig. 1.  
Role of TLRs and MyD88 in CHS in NOD mice.  (a) TLR2 and TLR9 and MyD88 deficiency 
in NOD mice showed an increased CHS response to PCl.  WT NOD (group B) or TLR2
-/-
 
(group D) or TLR9
-/-
 (group F) or MyD88
-/-
 (group H) NOD mice were sensitized with 5% 
PCl.  Four days later all the mice were challenged with 0.4% PCl and tested for CHS response 
24 h later.  N = 8-12, *p <0.05 and ***p <0.001 (ANOVA followed by Tukey’s test).  (b) 
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TLR2
-/-
 and TLR9
-/- 
and MyD88
-/-
 NOD mice develop stronger antigen specific responses in 
vitro. WT NOD mice (group A) or TLR2
-/-
 (group B) or TLR9
-/-
 (group C) or MyD88
-/-
 (group 
D) NOD mice were sensitized with 5% PCl.  Four days later ALNs were isolated and ALNC 
were cultured in the presence of the antigen, TNP40-Ig, at different concentration for 48 h.  
The mean background in cultures in the absence of the TNP-Ig for NOD, TLR2
-/-
NOD, TLR9
-
/-
NOD and MyD88
-/-
NOD was 10744±257, 24997±774, 10387±600 and 6440±570 
respectively.  N = 3, *p <0.05 and **p <0.01 (Two-tailed Student’s t-test).  All error bars 
represent SE. 
 
Fig. 2.  
Role of DCs in CHS in TLR- or MyD88-deficient NOD mice.  (a) Increased percentage of 
CD11c
+
I-A
g7+
 DCs expressing CD80 in TLR2 and TLR9 deficient NOD mice.  WT NOD 
(group B) or TLR2
-/-
 (group D) or TLR9
-/-
 (group F) NOD mice were sensitized with 5% PCl. 
Mice in negative controls (groups A, C and E) were not treated with PCl.   ALNs were 
isolated 3 days later and ALNC were stained with different monoclonal antibodies (anti-
CD11c-APC, anti-CD80-PE, anti-I-A
g7
-FITC).  Gating information for the flow analysis is 
presented in Fig. S2.  N=3, *p <0.05 and **p <0.01 (Two-tailed Student’s t-test).  (b) 
Increased percentage of CD11c
+
 I-A
g7+
 DCs expressing CD80 in MyD88
-/-
NOD mice. WT 
NOD (group B) or MyD88
-/-
NOD (group D) mice were sensitized with 5% PCl. Mice in 
negative controls (groups A and C) were not treated with PCl.  ALNs were isolated 3 days 
later and ALNC were stained with different monoclonal antibodies (anti-CD11c-APC, anti-
CD80-PE, anti-I-A
g7
-FITC).  Gating information for the flow analysis is presented in Fig. S2.  
N=3, **p <0.01 and ***p <0.001 (Two-tailed Student’s t-test). (c) CD11c
+
 cells isolated from 
MyD88
-/-
NOD mice are stronger inducers of CHS response than CD11c
+
 cells isolated from 
WT NOD mice.  Donor mice were immunized with PCl three days before the isolation of 
CD11c
+
 cells from ALN. Purified CD11c
+
 cells isolated from NOD (group B) or MyD88
-/-
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NOD (group C) mice were transferred s.c. into naïve NOD recipients, respectively.  The 
recipients were ear-challenged with 0.4% PCl after receiving the cells and tested for CHS 
responses 24 h later.  N=6-10, *p <0.05 and **p <0.01 and ***p <0.001 (Two-tailed 
Student’s t-test).  (d) Cytokine mRNA expression in skin homogenates. NOD (group A) and 
MyD88-/-NOD (group B) mice were sensitized with PCl. Five days later mRNA expression 
was measured in skin homogenates.  N=10-12, *p <0.05 (Mann Whitney’s test).  All error 
bars represent SE. 
 
Fig. 3.  
Re-expression of MyD88 in CD11c
+
 DCs restores normal CHS responses in MyD88
-/-
NOD 
mice.  (a) Presence of MyD88 in CD11c
+
 DCs restores normal CHS response in vivo.  WT 
NOD (group B) or MyD88
-/-
 (group D) or CD11c
MyD88+
MyD88
-/-
 (group F) NOD mice were 
sensitized with 5% PCl or not (group A, C and E, respectively).  Four days later all the mice 
were challenged with 0.4% PCl and tested for CHS 24 h after challenge.  N = 6-14, ***p 
<0.001 (Two-tailed Student’s t-test).  (b) CD11c
MyD88+
MyD88
-/-
NOD mice develop normal 
hapten specific response in vitro. WT NOD (group A) or MyD88
-/-
 (group B) or 
CD11c
MyD88+
MyD88
-/-
 (group C) NOD mice were sensitized with 5% PCl.  ALNs were 
isolated 4 days later and proliferation assay was performed as described in Fig. 2B.  N = 3, *p 
<0.05 and **p <0.01 (Two-tailed Student’s t-test).  (c) Presence of MyD88 in CD11c
+
 DCs 
restores normal IFN-γ production. WT NOD (group B) or MyD88-/- (group D) or 
CD11c
MyD88+
MyD88
-/-
 (group F) NOD mice were sensitized with 5% PCl or not (group A, C 
and E, respectively).   ALNs were isolated 4 days later and cultured in the presence of 
antigen, TNP40-Ig for 48 h.  Culture supernatants were harvested and tested for IFN-γ 
production by ELISA kit.  N = 6-12, ***p <0.001 (Two-tailed Student’s t-test or Mann 
Whitney’s test).  (d) Presence of MyD88 in CD11c
+
 DCs restores normal level of TNP-
specific IgG1 in serum. WT NOD (group B) or MyD88
-/-
 (group D) or CD11c
MyD88+
MyD88
-/-
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(group F) NOD mice were sensitized with 5% PCl or not (group A, C and E, respectively).  
Four days later, all the mice were challenged with 0.4% PCl.  The serum was collected 24 h 
after challenge.  Anti-TNP specific IgG1 antibody was measured by ELISA.  N = 6-24. ***p 
<0.001 (Two-tailed Student’s t-test or Mann Whitney’s test). All error bars represent SE. 
 
Fig. 4. 
Characterization and tracking of skin DCs in MyD88
-/- 
NOD mice.  (a) MyD88-deficient mice 
on the NOD background develop exaggerated CHS response to FITC.  WT NOD and MyD88
-
/-
NOD mice were sensitized with 0.5% FITC (groups B and D) or not (groups A and C).  The 
animals were challenged, 5days later, with FITC and tested for CHS response.  N = 4-10, 
***p <0.001 (ANOVA followed by Tukey’s test).  (b-g) Stronger migration and more 
activated phenotype of skin CD11c
+
 DCs in MyD88 deficient NOD mice.  WT NOD mice 
(group A), MyD88
-/-
 (group B) and CD11c
MyD88+
MyD88
-/-
 (group C) NOD mice were 
sensitized with 0.5% FITC.  Three days later, ALNs were isolated and stained with 
appropriate monoclonal antibodies: anti-I-A
g7
-biotin-strep-PE, anti-CD11c-PerCP-Cy5.5, 
anti-CD11c-APC, anti-CD80-APC, anti-CD86-APC, anti-CD103-PerCP-Cy5.5, anti-CD207-
PE.  Gating information for the flow analysis is presented in Fig. S2.  N = 3, *p <0.05 and **p 
<0.01 and ***p <0.001 (Two-tailed Student’s t-test).  All error bars represent SE. 
 
Fig. 5.   
Decreased ratio of CD4
+
CD25
+
FoxP3
+
 Tregs/ CD4
+
CD25
+
 activated T cells in ALNs and 
ELNs in MyD88
-/-
NOD mice.  (a) Frequencies of Tregs.  (b) Frequencies of T effector cells. 
(c) Ratio of CD4
+
CD25
+
FoxP3
+
 Tregs/ CD4
+
CD25
+
 activated T cells.  WT NOD mice (group 
A), MyD88
-/-
 (group B) and CD11c
MyD88+
MyD88
-/-
 (group C) NOD mice were sensitized with 
5% PCl.  Four days later, mice were challenged on both sides of the ears with PCl.  The ALNs 
and ELNs were collected 24 h after challenge.  ALNC and ELNC were stained with 
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monoclonal antibodies: anti-TCRβ-FITC, anti-CD4-PerCP-Cy5.5, anti-CD25-APC and anti-
FoxP3-PE.  Gating information for the flow analysis is presented in Fig. S2.  N = 3-4, *p 
<0.05; **p <0.01; *** p <0.001 (Two-tailed Student’s t-test).  All error bars represent SE.  
